Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

NCT07152418 | Not Yet Recruiting

• 1 other identifier: 2025-0466
• Study Type: observational
• Target: 120
• Locations: 0 countries
• Sites: N/A

Brief Summary

Preliminary clinical trial results indicate that Aβ-targeting monoclonal antibody drugs can delay disease progression more effectively. However, some patients still progress slowly to the moderate stage during treatment despite maintaining low Aβ/tau pathological protein loads. For such cases, patients and their families are fully informed about the potential lack of efficacy with continued treatment, and the decision is left to their discretion. Information regarding whether treatment is continued is documented and followed up to determine whether sustained benefits can be achieved. Previous further studies on lecanemab suggest that patients with low or absent tau pathology derive more significant clinical benefits, though large-sample validation remains lacking. This project will therefore enroll patients at clinical stages 3-4 (0.5 ≤ CDR ≤ 1) and monitor those progressing to moderate AD (CDR = 2) during monoclonal antibody therapy. Using tau pathology stratification, the study aims to identify which AD patients are most suitable for monoclonal antibody treatment and evaluate whether therapy continuation yields sustained benefits in patients progressing to moderate dementia, as well as whether patient selection should integrate both pathological (a-c stage) and clinical diagnoses.

Conditions

Alzheimer Disease (AD); Alzheimer Dementia; Mild Cognitive Impairment (MCI)

Keywords

Alzheimer Disease; lecanemab; Tau PET; Aβ PET

Outcome Measures

Primary Outcomes (1)

• Aβ-PET centiloid values

  Statistical Comparison of Lecanemab versus Conventional Anti-Dementia Treatment Based on Aβ-PET Centiloid Scores

  Baseline, 18 months

Secondary Outcomes (5)

• Change from Baseline in the CDR at 18 Months

  Baseline, 18 months

• Change from Baseline in the MMSE at 18 Months

  Baseline, 18 months

• Change from Baseline in the MoCA at 18 Months

  Baseline, 18 months

• Change from Baseline in the NPI at 18 Months

  Baseline, 18 months

• Blood AD molecular pathology

  Baseline, 6 months, 12 months, 18 months

Study Arms (2)

Lecanemab treatment group

Lecanemab 10 mg/kg

Biological: Lecanemab 10 mg/kg

Conventional anti-dementia treatment

Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.

Drug: Conventional anti-dementia treatment group

Interventions

Lecanemab 10 mg/kg BIOLOGICAL

Lecanemab Injection Concentrate Solution (active ingredient at 100 mg/mL) is provided as a sterile aqueous solution containing 100 mg/mL of Lecanemab, 50 mmol/L citric acid, 350 mmol/L arginine/arginine hydrochloride, and 0.05% (w/v) polysorbate 80, with a pH of 5.0, and each vial is capable of being drawn into a volume of 5 mL. Lecanemab is to be administered via intravenous infusion over 60 minutes in saline solution. Lecanemab must be administered using an infusion system that includes a terminal 0.22 μM inline filter. The dosage of Lecanemab is 10 mg/kg.

Lecanemab treatment group

Conventional anti-dementia treatment group DRUG

Conventional anti-dementia treatment: Early-stage Alzheimer's disease (AD) patients routinely take cholinesterase inhibitors such as donepezil for treatment.

Conventional anti-dementia treatment

Eligibility Criteria

• Age: 50 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study included early AD patients treated with Lecanemab and Conventional Anti-Dementia Treatment at the Second Affiliated Hospital of Zhejiang University School of Medicine.

You may qualify if:

• Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) due to Alzheimer's Disease or mild-to-moderate AD. \[Clinical Scores: CDR Global Score = 0.5 (for MCI) or 1 (for mild AD), corresponding to clinical stages 3-4, with a positive PIB-PET scan confirming amyloid pathology\]
• Male or Female
• Between 50 and 85 years old (inclusive)
• Not currently participating in any other clinical trial or research study
• Participants must provide informed consent for this trial prior to enrollment and must voluntarily sign a written informed consent form
• Participants must be able to communicate effectively with the investigator and are expected to comply with the study requirements to completion

You may not qualify if:

• Any contraindication to MRI
• History of seizure within the past 6 months or refractory epilepsy.
• Unstable or severe psychiatric illness within the past 6 months.
• History of bleeding disorders, coagulopathy, or clinically significant coagulation abnormalities (e.g., platelet count \<50,000/μL or INR \>1.5).
• Uncontrolled diabetes mellitus or hypertension.
• History of unstable angina, myocardial infarction, advanced heart failure, or clinically significant conduction abnormalities within the past year.
• Active cancer treatment (e.g., chemotherapy, biologics, or radiation therapy), except maintenance therapy for cancers in remission (e.g., anti-estrogen therapy for breast cancer).
• Immunological disorders requiring ongoing immunosuppression, immunoglobulin therapy, monoclonal antibodies, or plasmapheresis.
• Breastfeeding individuals or women of childbearing potential not using highly effective contraception.
• History of severe allergic, anaphylactic reactions, or hypersensitivity to any inactive ingredients.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

MeSH Terms

Conditions

Alzheimer Disease; Cognitive Dysfunction

Interventions

lecanemab

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Cognition Disorders

Central Study Contacts

Jiong Zhou, M.D.

CONTACT

+86 139 5812 5492; ze-zj@zju.edu.cn

Yaping Yan

CONTACT

+86 151 6831 2676; yanyaping@zju.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 18 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2025
• First Posted: September 3, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): September 1, 2028
• Last Updated: September 3, 2025

Record last verified: 2025-06